Prognostic value of myeloperoxidase in patients with chest pain.

  title={Prognostic value of myeloperoxidase in patients with chest pain.},
  author={Marie-Luise Brennan and Marc S. Penn and Frederick van Lente and Vijay Nambi and Mehdi H. Shishehbor and Ronnier J. Aviles and Marlene Goormastic and Michael Pepoy and Ellen S McErlean and Eric J. Topol and Steven E. Nissen and Stanley L. Hazen},
  journal={The New England journal of medicine},
  volume={349 17},
BACKGROUND Inflammation is linked to adverse outcomes in acute coronary syndromes. Myeloperoxidase, an abundant leukocyte enzyme, is elevated in culprit lesions that have fissured or ruptured in patients with sudden death from cardiac causes. Numerous lines of evidence suggest mechanistic links between myeloperoxidase and both inflammation and cardiovascular disease. METHODS We assessed the value of plasma levels of myeloperoxidase as a predictor of the risk of cardiovascular events in 604… 

Figures and Tables from this paper

Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome

Myeloperoxidase, in contrast to troponin and CK-MB, identified patients at risk of ischaemic events, even in the absence of myocardial necrosis, thus highlighting its potent usefulness for risk stratification among patients presenting with chest pain.

Myeloperoxidase to Risk Stratify Emergency Department Patients with Chest Pain

In this limited cohort of low risk ED patients with chest pain, the utility of MPO for risk stratification is unable to be demonstrated, and this findings may call into question the routine use ofMPO for low-risk chest pain.

Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain.

In patients with acute chest pain and no ST elevation, high MPO levels upon admission to the hospital are an important tool to predict in-hospital adverse events, with an odds ratio of eight for the diagnosis of AMI.

Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients

Elevated MPO levels among the ACS patients suggest that this marker may participate in plaque vulnerability and instability process, whereas higher CRP levels were predictive of cardiac events only among the stable angina patients.

Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy

Serum MPO levels were found to be a strong predictor of response to thrombolytic treatment in patients with ST-segment elevation myocardial infarction, and the level of inflammatory activity in acute coronary syndromes seems to influence the effectiveness of fibrinolysis.

Study of Myeloperoxidase level in Coronary Artery Disease patients from tertiary care Hospital

Plasma levels of MPO and Serum total CPK, CK-MB, LDH, CRP, uric acid and lipid profile levels along with Troponin T were measured in all patients of CAD to investigate their role as diagnostic biochemical parameter in coronary artery disease.

Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction.

Evaluation of plasma myeloperoxidase levels might be useful in determining patients at high risk of death and MACE who can benefit from further aggressive treatment and closer follow-up.

Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations.

A combination of MPO and cTnI allowed the identification of a greater proportion of patients at risk for MACE than the use of cT nI alone, and increased MPO values remained predictive of future cardiac events even when the cTNI value was normal.



Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndromes

The observations suggest that neutrophil infiltration is actively associated with acute coronary events, and the high number of NEP-positive neutrophils in ruptured plaques, compared with eroded plaques may reflect differences in the underlying pathophysiological mechanisms.

Association between myeloperoxidase levels and risk of coronary artery disease.

Elevated levels of leukocyte- and blood-MPO are associated with the presence of CAD, and a potential role for MPO as an inflammatory marker in CAD is supported and may have implications for atherosclerosis diagnosis and risk assessment.

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

In patients with acute coronary syndromes, cardiac troponin I levels provide useful prognostic information and permit the early identification of patients with an increased risk of death.

Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease.

Data suggest that CRP, probably with different cut-offs, should be used as a marker of risk and as a guide to therapy in patients hospitalized for acute coronary syndromes and in outpatients suffering from ischemic heart disease.

The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Elevation of the sensitive acute-phase proteins C-reactive protein and serum amyloid A protein at the time of hospital admission predicts a poor outcome in patients with unstable angina and may reflect an important inflammatory component in the pathogenesis of this condition.

Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide

Troponin, CRP, and BNP each provide unique prognostic information in patients with ACS and a simple multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation allows risk stratification over a broad range of short- and long-term major cardiac events.

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events.

Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.

The pathologic process in sudden ischemic death involves a rapidly evolving coronary-artery lesion in which plaque fissuring and resultant thrombus formation are present, and these findings have implications for the prevention of sudden cardiac death by antithrombotic therapy.